VEGFA and neoplasm: The VEGF protein and its receptors have been implicated as a major pathway associated with tumor angiogenesis and targeted VEGF inhibition constitutes an FDA-approved treatment approach in CC, renal cell carcinoma (RCC), and hepatocellular carcinoma (HCC) patients [49,50].